首页> 外文期刊>Biological & pharmaceutical bulletin >N-Acetyltransferase 2 Genotype Correlated with Isoniazid Acetylation in Japanese Tuberculous Patients
【24h】

N-Acetyltransferase 2 Genotype Correlated with Isoniazid Acetylation in Japanese Tuberculous Patients

机译:N-乙酰基转移酶2基因型与日本结核患者异烟肼乙酰化相关。

获取原文
获取原文并翻译 | 示例
       

摘要

Isoniazid (INH) is metabolized by polymorphic N-acetyltransferase2 (NAT2). In the present study, the relationship between the NAT2 genotype and the INH acetylator phenotype was examined in Japanese tuberculous patients and compared with healthy subjects. Subjects were classified according to the genotyping into NAT2~*5B (allele4), NAT2~*6A (allele3) and NAT2~*7B (allele2), using the PCR-RFLP method. Twelve healthy subjects and 7 tuberculous patients participated in the INH acetylator phenotyping study, in which each subject was administered an oral dose of INH, followed by urine sampling for 24h. Urinary concentrations of INH and N-acetylisoniazid (AcINH) were measured by the HPLC method. The urinary recoveries of INH (% of dose) in healthy subjects in relation to NAT2 genotyping were as follows: 6.4 ± 2.2 in the homozygotes for the wild-type allele, 10.7 ± 2.2 in the compound heterozygotes for the mutant allele, and 38.6 ± 6.4 in the homozygotes for the mutant allele. In the patients study, the findings in the corresponding three groups were 4.0 ± 1.7, 8.8 and 18.3 ± 9.3. Although no significant difference was found because of the lower systemic exposure of INH in patients compared with healthy subjects, there were differences in the disposition kinetics of INH between subjects with an without mutations in the NAT2 gene, and these findings were observed not only in healthy subjects but also in patients who had comedicated drugs and hepatic dysfunctions. The findings indicated that the metabolism of INH by NAT2 is clearly impaired in subjects with muations in the NAT2 gene, and thus genotyping for three NAT2 point mutations was adequate to predict the metabolism of INH in Japanese tuberculous parients as well as healthy subjects. This NAT2 genotyping could become a useful alternative to TDM for INH.
机译:异烟肼(INH)被多态性N-乙酰基转移酶2(NAT2)代谢。在本研究中,检查了日本结核病患者中NAT2基因型与INH乙酰化表型之间的关系,并与健康受试者进行了比较。使用PCR-RFLP方法,根据基因型将受试者分为NAT2〜* 5B(等位基因4),NAT2〜* 6A(等位基因3)和NAT2〜* 7B(等位基因2)。 12名健康受试者和7名结核病患者参加了INH乙酰化仪表型研究,在该研究中,每个受试者都口服了INH剂量,然后进行了24小时尿液采样。通过HPLC方法测定尿中INH和N-乙酰基异烟肼(AcINH)的浓度。与NAT2基因型相关的健康受试者的INH尿回收率(剂量的百分比)如下:野生型等位基因的纯合子为6.4±2.2,突变型等位基因的复合杂合子为10.7±2.2,38.6± 6.4中纯合子为突变等位基因。在患者研究中,相应三组的结果分别为4.0±1.7、8.8和18.3±9.3。尽管与健康受试者相比,由于患者体内INH的全身暴露量较低,未发现明显差异,但在NAT2基因无突变的受试者之间,INH的处置动力学存在差异,并且不仅在健康人群中观察到了这些发现受试者,还包括患有药物和肝功能障碍的患者。这些发现表明,在NAT2基因突变的受试者中,NAT2对INH的代谢明显受损,因此对三个NAT2点突变的基因分型足以预测日本结核病患者和健康受试者的INH代谢。这种NAT2基因分型可以成为INH的TDM的有用替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号